Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Biocardia Inc (BCDA)

Biocardia Inc (BCDA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 48,509
  • Shares Outstanding, K 20,045
  • Annual Sales, $ 1,020 K
  • Annual Income, $ -12,620 K
  • 60-Month Beta 1.06
  • Price/Sales 31.80
  • Price/Cash Flow N/A
  • Price/Book 10.36
Trade BCDA with:

Options Overview Details

View History
  • Implied Volatility 99.38% ( +6.34%)
  • Historical Volatility 51.81%
  • IV Percentile 9%
  • IV Rank 8.08%
  • IV High 816.86% on 05/09/22
  • IV Low 36.30% on 06/16/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 262
  • Put/Call OI Ratio 0.54
  • Today's Open Interest 10,469
  • Open Int (30-Day) 7,831

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.17
  • Number of Estimates 2
  • High Estimate -0.13
  • Low Estimate -0.22
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +19.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.82 +32.97%
on 12/28/22
2.47 -2.02%
on 01/26/23
+0.59 (+32.24%)
since 12/27/22
3-Month
1.56 +55.13%
on 12/13/22
2.47 -2.02%
on 01/26/23
+0.45 (+22.84%)
since 10/27/22
52-Week
1.10 +119.98%
on 05/12/22
2.85 -15.09%
on 04/12/22
+0.91 (+60.26%)
since 01/27/22

Most Recent Stories

More News
BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced Food and Drug Administration (FDA) approval...

BCDA : 2.42 (+2.98%)
BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 26.09% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

BCDA : 2.42 (+2.98%)
URGN : 9.35 (+11.31%)
BioCardia, Inc. (BCDA) Upgraded to Buy: Here's What You Should Know

BioCardia, Inc. (BCDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BCDA : 2.42 (+2.98%)
Alector (ALEC) Reports Q3 Loss, Lags Revenue Estimates

Alector (ALEC) delivered earnings and revenue surprises of -30.23% and 71.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ALEC : 9.16 (+2.12%)
BCDA : 2.42 (+2.98%)
Has BioCardia (BCDA) Outpaced Other Medical Stocks This Year?

Here is how BioCardia, Inc. (BCDA) and Ensign Group (ENSG) have performed compared to their sector so far this year.

BCDA : 2.42 (+2.98%)
ENSG : 91.38 (-0.75%)
BioCardia, Inc. (BCDA) Reports Q2 Loss, Tops Revenue Estimates

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 50% and 412.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

BCDA : 2.42 (+2.98%)
ARDS : 0.7099 (-11.26%)
BioCardia Reports Second Quarter 2022 Business Highlights And Financial Results

SUNNYVALE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the...

BCDA : 2.42 (+2.98%)
YmAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Lags Revenue Estimates

YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -38.24% and 5.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

YMAB : 4.44 (-2.42%)
BCDA : 2.42 (+2.98%)
BioCardia to Host Q2 2022 Financial Results and Corporate Update Conference Call on August 10, 2022

SUNNYVALE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the...

BCDA : 2.42 (+2.98%)
BioCardia Announces First Canadian Clinical Site for CardiAMP Cell Therapy Heart Failure Trial

SUNNYVALE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the...

BCDA : 2.42 (+2.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BioCardia Inc. is engaged in developing regenerative biologic therapies to treat cardiovascular disease. The company's product candidate consists of CardiAMP(TM), CardiALLO(TM) and Helix Biotherapeutic Delivery System(TM) in clinical development stage. BioCardia Inc. is headquartered in San Carlos, California....

See More

Key Turning Points

3rd Resistance Point 2.60
2nd Resistance Point 2.53
1st Resistance Point 2.47
Last Price 2.42
1st Support Level 2.34
2nd Support Level 2.27
3rd Support Level 2.21

See More

52-Week High 2.85
Last Price 2.42
Fibonacci 61.8% 2.18
Fibonacci 50% 1.98
Fibonacci 38.2% 1.77
52-Week Low 1.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar